Pathobiological Implications of MUC16/CA125 Expression in Intrahepatic Cholangiocarcinoma-Mass Forming Type

被引：80
|
作者：
Higashi, Michiyo [1 ]
Yamada, Norishige [1 ]
Yokoyama, Seiya [1 ]
Kitamoto, Sho [1 ]
Tabata, Kazuhiro [1 ]
Koriyama, Chihaya [2 ]
Batra, Surinder K. [3 ,4 ]
Yonezawa, Suguru [1 ]
机构：
[1] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Human Pathol, Field Oncol, Kagoshima 8908544, Japan
[2] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Epidemiol & Prevent Med, Kagoshima 8908544, Japan
[3] Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Dept Biochem, Omaha, NE USA
[4] Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Dept Mol Biol, Omaha, NE USA
来源：
PATHOBIOLOGY | 2012年 / 79卷 / 02期
关键词：
Cholangiocarcinoma; MUC16; CA125; Prognosis; PROGNOSTIC-FACTOR; EXTRACELLULAR SUPERSTRUCTURE; SURGICAL-TREATMENT; CA-125; GENE; MUC4; MUCINS; CA125; NEOPLASMS; CARCINOMA; DIAGNOSIS;
D O I：
10.1159/000335164
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
Objectives: MUC16 carries the peptide epitope CA125, which is well known as a marker of ovarian cancer. High serum levels of MUC16 (CA125) have been reported not only in patients with ovarian cancer but also in patients with liver diseases. We evaluated the expression of MUC16 in intrahepatic cholangiocarcinoma-mass forming type (ICC-ME) tissues. Methods: We examined the expression of MUC16 by immunohistochemical analyses using the monoclonal antibody M11 in ICC-MF tissues from 63 patients. To compare the prevalence of each mucin expression by clinicopathological features, appropriate statistical analysis was performed. Results: MUC16 was detected in 48% of samples (30/63). After adjusting for the effects of other prognostic factors, multi-variate survival analysis revealed that MUC16 expression is a significant independent factor of poor prognosis (p = 0.005). Conclusion:The current results indicate that MUC16 expression is a prognostic factor of poor survival in ICC-MF. Copyright (C) 2012 S. Karger AG, Basel
引用
收藏
页码：101 / 106
页数：6
相关论文
共 50 条
  • [31] MUC16/CA125 synthetic lethal kinase screen for novel ovarian cancer targets
    Eng, Stephanie
    Robin, Manson
    Zhou, Qin C.
    Thapi, Dharmar O.
    Roslaes, Nestor
    Iasonos, Alexia
    Spriggs, David R.
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [32] A biosensor for determination of the circulating biomarker CA125/MUC16 by Surface Plasmon Resonance Imaging
    Szymanska, B.
    Lukaszewski, Z.
    Hermanowicz-Szamatowicz, K.
    Gorodkiewicz, E.
    TALANTA, 2020, 206
  • [33] Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion
    Rump, A
    Morikawa, Y
    Tanaka, M
    Minami, S
    Umesaki, N
    Takeuchi, M
    Miyajima, A
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (10) : 9190 - 9198
  • [34] Immune cell bound MUC16 (CA125): A novel diagnostic marker for ovarian cancer
    Belisle, Jennifer A.
    Felder, Mildred
    Kapur, Arvinder
    Tyler, Chanel T.
    Connor, Joseph P.
    Patankar, Manish S.
    CANCER RESEARCH, 2011, 71
  • [35] Synthesis and structural characterization of the peptide epitope of the ovarian cancer biomarker CA125 (MUC16)
    Berman, Zach T.
    Moore, Lee J.
    Knudson, Kathleen E.
    Whelan, Rebecca J.
    TUMOR BIOLOGY, 2010, 31 (05) : 495 - 502
  • [36] Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16
    Casey, Nicholas P.
    Kleinmanns, Katrin
    Forcados, Christopher
    Gelebart, Pascal F.
    Joaquina, Sandy
    Lode, Martine
    Benard, Emmanuelle
    Kaveh, Fatemeh
    Caulier, Benjamin
    Helgestad Gjerde, Christiane
    de Jalon, Elvira Garcia
    Warren, David J.
    Lindemann, Kristina
    Rokkones, Erik
    Davidson, Ben
    Myhre, Marit Renee
    Kvalheim, Gunnar
    Bjorge, Line
    McCormack, Emmet
    Inderberg, Else Marit
    Walchli, Sebastien
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (04)
  • [37] The role of the ovarian tumor marker CA125 (MUC16) in the suppression of human immune responses
    Belisle, JA
    Arens, JA
    Migneault, M
    Rancourt, C
    Felder, M
    Connor, J
    Patankar, MS
    JOURNAL OF IMMUNOTHERAPY, 2005, 28 (06) : 635 - 636
  • [38] MUC16/CA125, TNFα and IFNγ are co-expressed in malignant gynecologic neoplasms
    Morgado, Micaela
    Sutton, Margie N.
    Simmons, Mary
    Liu, Jinsong
    Lu, Zhen
    Papadopoulos, Pamela E.
    Bast, Robert C.
    Carson, Daniel D.
    CANCER RESEARCH, 2015, 75
  • [39] Molecular cloning of the CA125 ovarian cancer antigen - Identification as a new mucin, MUC16
    Yin, BWT
    Lloyd, KO
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (29) : 27371 - 27375
  • [40] MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis
    Theriault, Catherine
    Pinard, Maxime
    Comamala, Marina
    Migneault, Martine
    Beaudin, Julie
    Matte, Isabelle
    Boivin, Marianne
    Piche, Alain
    Rancourt, Claudine
    GYNECOLOGIC ONCOLOGY, 2011, 121 (03) : 434 - 443
12345